Premium
Prognostic value of epidermal growth factor receptor amplification and EGFR v III in glioblastoma: meta‐analysis
Author(s) -
Chen J.R.,
Xu H.Z.,
Yao Y.,
Qin Z.Y.
Publication year - 2015
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.12401
Subject(s) - glioblastoma , epidermal growth factor receptor , value (mathematics) , oncology , medicine , meta analysis , epidermal growth factor , cancer research , receptor , statistics , mathematics
Objectives Epidermal growth factor receptor ( EGFR ) gene amplification and the EGFR v III mutation may have prognostic value in patients with glioblastoma. This meta‐analysis was to determine whether EGFR gene amplification or the EGFR v III mutation are predictors of survival in patients with glioblastoma and anaplastic astrocytoma. Materials and methods Medline, the Cochrane Central Register of Controlled Trials, EMBASE , and Google Scholar databases were searched until July 31, 2014. Studies were selected for inclusion in the analysis if they included patients with anaplastic astrocytoma and/or glioblastoma, EGFR and/or EGFR v III mutation status was reported, and overall survival ( OS ) data were reported. Results Of 113 articles initially identified, only eight contained data with respect to the outcome of interest and were included in the meta‐analysis. The number of cases ranged from 14 to 268, and the majority of patients were 60 or more years of age. There was no significant difference in OS between EGFR amplification‐positive and EGFR amplification‐negative glioblastoma patients (pooled hazard ratio [ HR ] = 1.101, 95% confidence interval [ CI ] 0.845, 1.434, P = 0.475) or anaplastic astrocytoma patients (pooled HR = 1.455, 95% CI 0.852, 2.482, P = 0.169). There was no significant difference in OS between EGFR v III ‐positive and EGFR v III ‐negative glioblastoma patients (pooled HR = 1.321, 95% CI : 0.881–1.981, P = 0.178). Significant heterogeneity existed between the studies, and the significance changed when the analysis was performed with studies removed in turn. Conclusions There is insufficient evidence that either EGFR amplification or the EGFR v III mutation has prognostic value in patients with glioblastoma.